Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kentarou Asahi"'
Autor:
Yasuhiko Kanda, Maki Tomari, Tohru Horiguchi, Kayoko Hata, Hiroyuki Kai, Emiko Taniguchi, Tsuyoshi Hasegawa, Shunji Shinohara, Takayuki Kameyama, Yoshiyuki Taoda, Miho Oohara, Shinji Shimada, Yukio Takahara, Yoshikazu Tanaka, Naoko Kurihara, Yukio Tada, Hiroyuki Tobinaga, Chie Takeyama, Shigenori Yagi, Shoichi Yamamoto, Fumiyo Takahashi, Kentarou Asahi
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 30:127636
The P2X3 receptor is an attractive target for the treatment of pain and chronic coughing, and thus P2X3 antagonists have been developed as new therapeutic drugs. We previously reported selective P2X3 receptor antagonists by derivatization of hit comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c89d73a5579aa30dce0898c8270420b
https://doi.org/10.1016/j.bmcl.2020.127636
https://doi.org/10.1016/j.bmcl.2020.127636
Autor:
Takeshi Endoh, Chie Takeyama, Yasuhiko Kanda, Kentarou Asahi, Hiroyuki Tobinaga, Naomi Tamura, Yukio Tada, Naoko Kurihara, Miho Oohara, Shinji Shimada, Shigenori Yagi, Shunji Shinohara, Masayoshi Ogawa, Shoichi Yamamoto, Tohru Horiguchi, Hiroyuki Kai, Kouki Fuchino, Yukio Takahara, Emiko Taniguchi, Takayuki Kameyama, Sae Jikihara
Publikováno v:
Bioorganicmedicinal chemistry letters. 29(5)
Some P2X3 receptor antagonists have been developed as new therapeutic drugs for pain. We discovered a novel chemotype of P2X3 receptor antagonists with a pyrrolinone skeleton. Because of SAR studies to improve bioavailability of lead compound 2, comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca76eb6851bccd95fe5b1c823f942155
https://pubmed.ncbi.nlm.nih.gov/30728111
https://pubmed.ncbi.nlm.nih.gov/30728111